Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5875889 | The American Journal of Medicine | 2014 | 56 Pages |
Abstract
These meta-analysis updates of the comparative safety of tumor necrosis factor inhibitors suggest a higher risk of serious infection associated with adalimumab, certolizumab pegol, and infliximab, which seems to contribute to higher rates of discontinuation. In contrast, etanercept use showed a lower rate of discontinuation. These data may help guide clinical comparative decision making in the management of rheumatoid arthritis.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Tzeyu L. MHA, Young Hee MD, PhD, MPH, Tatyana MD, MS, Karen M. ScD, Hyon K. MD, DrPH,